Category

Daily Briefs

Daily Brief Health Care: Yichang HEC Changjiang Pharma, Basilea Pharmaceutica Ag and more

By | Daily Briefs, Healthcare

In today’s briefing:

  • Yichang HEC (1558 HK): Absorption Via Speculative Scrip. Avoid
  • Basilea Pharmaceutica – Cresemba milestone payments continue to roll in


Yichang HEC (1558 HK): Absorption Via Speculative Scrip. Avoid

By David Blennerhassett

  • A “Privatisation via a Merger by Absorption” is nothing new in Hong Kong. But the Offer consideration for Yichang HEC (1558 HK)‘s minorities is in unlisted scrip – that’s new. 
  • The Offeror holds 51.41% in Yichang HEC. Founder Guo Meilan and her son Zhang Yushuai control 62.12% of the Offeror. Yichang HEC shareholders are being offered 0.263614 “Offeror H shares”.
  • These consideration shares are unlisted. An independent valuer backs out an implied scrip value of HK$18.12-HK$20.60/share. This is a super complicated, overwrought deal. With numerous unknowns. I’d vote this down. 

Basilea Pharmaceutica – Cresemba milestone payments continue to roll in

By Edison Investment Research

Basilea Pharmaceutica has announced the triggering of a US$1.25m milestone payment from Pfizer, triggered by sustained strong sales of Cresemba in the Asia-Pacific region and China. This is the second FY24 milestone payment for the region and is incremental to the payment received in March. We note that, according to the latest available data, total in-market sales of Cresemba amounted to US$473m in the 12 months ending December 2023, representing a +26% year-on-year increase. Basilea is preparing to launch its Phase III programme for fosmanogepix, a broad-spectrum antifungal therapy, with the first of two Phase III trials expected to initiate in mid-2024. The company also made positive regulatory and operational strides with its lead antibiotic asset, Zevtera (following FDA approval in April 2024), and we eagerly await the announcement of a potential US commercial partner.


💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Consumer: Li Auto , KraneShares CSI China Internet ETF, Dentsu Inc and more

By | Consumer, Daily Briefs

In today’s briefing:

  • HSTECH June 2024 Rebal – No Changes But Big Capping Flows, As Expected; 8% US$1.6bn One-Way
  • Red Dragon Awakening
  • Dentsu Group – FY24 prospects weighted to H2


HSTECH June 2024 Rebal – No Changes But Big Capping Flows, As Expected; 8% US$1.6bn One-Way

By Travis Lundy

  • The Hang Seng Tech Index is more widely-followed than many think, and it is reasonably concentrated, so outperformance and underperformance by big names means capping and re-capping.
  • This time, those flows are worth about 8% of the index in terms of one-way flows. Meituan, Xiaomi, JD.com, Tencent and Kuaishou Tech DOWN. Li Auto back up. 
  • Those who have pre-positioned on the big buy have recently gotten hurt. There are some FAF changes which are less predictable and may be interesting.

Red Dragon Awakening

By Douglas Busch

  • China momentum continues with KWEB breaking out above WEEKLY double-bottom base
  • Stocks REPORTING this week that look technically sound include PDD BZ and EH
  • In-Depth look at individual leaders in Tencent Holdings, Futu Holdings, and Sony Group

Dentsu Group – FY24 prospects weighted to H2

By Edison Investment Research

Dentsu’s Q1 results indicate a slow start to the year, with organic net revenue down by 3.7%. However, prospects are improving, buoyed by new business wins and weighted to H2, which leave full year expectations (and our forecasts) unchanged. The One dentsu initiative, bringing together skill sets in consulting, technology, media and creative, is supporting improved pitch win rates, and giving greater coherence and consistency to the group product and service offering. We expect this to be a central element of the new management medium-term strategy, set to be unveiled during H2. The rating remains at a substantial discount to global peers, which we anticipate will narrow as evidence of renewed growth builds.


💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Top 10 Highlights from the APAC PE, VC and Startup Ecosystem this Week – 19 May 2024

By | Private Markets, Smartkarma Newswire

Top ten highlights from the APAC PE, VC, and startup ecosystem this week:

  1. China Tech Giants’ Earnings: Companies like Alibaba, Tencent, Baidu, and JD.com reported mixed financial updates this week.
  2. Sea Ltd’s Q1 Earnings: Sea reported a net loss of $23 million in Q1 2024, with a 23% year-on-year revenue growth from its e-commerce arm, Shopee.
  3. Grab’s Revenue Growth: Grab’s revenue grew by 24% in Q1 to $653 million, prompting an upward revision of its full-year adjusted EBITDA guidance.
  4. Mubadala’s Asset Growth: Abu Dhabi’s Mubadala saw a 9.5% increase in assets under management in 2023, reaching 1.11 trillion dirhams.
  5. CapitaLand’s Investment Outlook: CapitaLand Investment anticipates a promising vintage for real asset investments in the Asia Pacific in 2025.
  6. Waterfield Fund of Funds Perspective: Waterfield Fund of Funds MD, Siddharth Jhunjhunwala, shared insights on India’s dealmaking scenario and its impact on capital flow from LPs.
  7. ShawKwei’s Investment Strategy: ShawKwei is actively considering investment opportunities in the secondary space due to favorable valuation landscapes.
  8. Saudi Venture Capital Investment: Saudi Venture Capital announced a $30 million investment in a PE fund managed by General Atlantic.
  9. China Life Insurance Fund: China Life Insurance established an RMB-denominated equity investment fund of 10 billion yuan for the country’s silver economy.
  10. Accion’s Financial Fund: Global non-profit Accion launched a $152.5 million fund to invest in financial institutions serving small businesses globally.

APAC Private Markets Research

Explore latest Insights on APAC Private Markets on Smartkarma


Disclaimer:This article by is general in nature and based on publicly available information and not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material. While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.


 

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Analytics and News
  • ✓ Events & Webinars

Also, check out the latest in ECM Research on Smartkarma